Vielight Neuro Gamma (Brain Photobiomodulation Device) 40 Hz Pulse | 810 nm (near infrared) energy
Price includes GST & FREE SHIPPING to Australia and New Zealand | Ships from Melbourne
The Vielight Neuro Gamma is a powerful device featuring improved transcranial clusters and updated microchip LED boosting technology – leading to triple the previous power density and a refined form factor that fits a wider variety of head shapes and sizes.
DOWNLOAD – Neuro-Gamma-User-Guide
The design of the Vielight Neuro
The Vielight Neuro Gamma is similar in design to the Neuro Alpha – the only difference resides in the pulse rate. The power density and wavelength is the same.
Theoretically, the more intense 40-Hz pulse rate, which correlates with gamma (γ) oscillations within the brain, is associated with activating glial cells which clear unwanted protein deposits, higher cognitive processing capability and memory consolidation.
- In neuroscience, the Default Mode Network (DMN) is a network of highly interactive brain regions.
- Research on DMN abnormalities and related neuropathologies are highly advanced.
- Targeting the DMN enables us to utilize fewer but very high-powered diodes in specific transcranial areas and an intranasal diode (5 areas in total) to deliver low level photons to the targeted network hubs.
- Our microchip LED technology allows extraction of a higher power density – sufficient to penetrate natural barriers and deliver photons to neurons.
Independent Research (utilizing Vielight technology)
The Gamma is being used in several ongoing clinical trials in several sites across North America.
Do you want more information on the clinical studies? See Below:
University of California, San Francisco
Vielight Research [Ongoing]
(2018 Winter) Neuro RX Gamma – Pivotal Phase Trial (Phase III Trial)
Direct access to information on pilot study on clinicaltrials.gov – (clinicaltrials.gov, U.S. National Institutes of Health) Click Here
An IRB-approved large study evaluating the feasibility, safety, and efficacy of the Vielight Neuro Gamma for the treatment of moderate-to-severe Alzheimer’s Disease.
For further information on these clinical studies and other past and ongoing studies, click here.